On February 2, 2017 The Ministry of Health and Family Welfare has announced Medical Devices Rules, 2017 that separates regulatory norms for manufacturing medical devices from drugs. The rules will come into effect from January 1, 2018.
This new rules is to regulate medical devices in the country to ease norms for manufacturing medical devices in the country and to promote domestic industry. The new rules also have eased standard for obtaining license and conducting clinical trials, and also reduced interface between manufacturer and regulator by promoting digital platform.
The government has observed to the industry’s nearly decade long demand of separating it from pharmaceutical industry so that the same powerful laws that regulate drugs are not applicable to medical devices. The rules have a provision for awarding compensation up to ₹8 lakh to people impacted by trials adversely.
The Health Ministry joint secretary KL Sharma said, “Till now medical devices were regulated as drugs but now we have separated the two and formed rules specifically catering to the medical devices industry,” Medical devices have been classified in four categories based on their risk type (Class A, B, C and D). Central government will be directly involved in approvals and licensing of devices falling under category C & D.
The industry will no longer have to follow tough clinical trial guidelines spanning 4 phases, like in case of drug trials. Only a pilot study on smaller population to test safety and performance of the device and later a trial on pivotal basis on a larger population, The rules are designed to standardize and regulate medical devices manufacturing industry, as good as international standards. The new rules have been framed in conformity with Global Harmonisation Task Force (GHTF) framework and follow best international practices.
The action will boost government’s ‘Make in India’ campaign by providing favorable environment for domestic manufacturers that could lead to greater long term investments.
Other News
India Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read MoreErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read MoreTUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More